Prognostic Alternative Splicing Signatures in Esophageal Carcinoma

Zodwa Dlamini1 SAMRC Precision Prevention & Novel Drug Targets for HIV-Associated Cancers Extramural Unit, Pan African Cancer Research Institute, University of Pretoria, Pretoria, South AfricaCorrespondence[email protected]

https://orcid.org/0000-0002-8012-3646

Rodney Hull1 SAMRC Precision Prevention & Novel Drug Targets for HIV-Associated Cancers Extramural Unit, Pan African Cancer Research Institute, University of Pretoria, Pretoria, South Africa

https://orcid.org/0000-0002-2001-3453

Sikhumbuzo Z Mbatha2 Department of Surgery, Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa

Mohammed Alaouna1 SAMRC Precision Prevention & Novel Drug Targets for HIV-Associated Cancers Extramural Unit, Pan African Cancer Research Institute, University of Pretoria, Pretoria, South Africa;3 Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

https://orcid.org/0000-0002-1382-2332

You-Lin Qiao1 SAMRC Precision Prevention & Novel Drug Targets for HIV-Associated Cancers Extramural Unit, Pan African Cancer Research Institute, University of Pretoria, Pretoria, South Africa;4 Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China

https://orcid.org/0000-0001-6380-0871

Herbert Yu1 SAMRC Precision Prevention & Novel Drug Targets for HIV-Associated Cancers Extramural Unit, Pan African Cancer Research Institute, University of Pretoria, Pretoria, South Africa;5 University of Hawaii Cancer Center, Honolulu, HI, USA

https://orcid.org/0000-0003-3950-4815

Aristotelis Chatziioannou1 SAMRC Precision Prevention & Novel Drug Targets for HIV-Associated Cancers Extramural Unit, Pan African Cancer Research Institute, University of Pretoria, Pretoria, South Africa;6 Center of Systems Biology, Biomedical Research Foundation Academy of Athens, Athens, Greece;7 e-NIOS Applications PC, Kallithea, Athens, 17676, Greece

https://orcid.org/0000-0003-2078-0844

show all

Abstract

Alternative splicing (AS) is a method of increasing the number of proteins that the genome is capable of coding for, by altering the pre-mRNA during its maturation. This process provides the ability of a broad range of proteins to arise from a single gene. AS events are known to occur in up to 94% of human genes. Cumulative data have shown that aberrant AS functionality is a major factor in human diseases. This review focuses on the contribution made by aberrant AS functionality in the development and progression of esophageal cancer. The changes in the pattern of expression of alternately spliced isoforms in esophageal cancer can be used as diagnostic or prognostic biomarkers. Additionally, these can be used as targets for the development of new treatments for esophageal cancer.

Keywords:

Acknowledgment

The authors would like to thank the South African Medical Research Council (SAMRC) for funding this research.

Disclosure

Aristotelis Chatziioannou reports being the CEO of e-NIOS APPLICATIONS PC, during the conduct of the study; and that as CEO and CSO they direct the research activities of e-NIOS APPLICATIONS PC, outside the submitted work. The authors report no other potential conflicts of interest in this work.

Prognostic Alternative Splicing Signatures in Esophageal Carcinoma

Information for

Open access

Opportunities

Help and information

Prognostic Alternative Splicing Signatures in Esophageal Carcinoma

Abstract

Acknowledgment

Disclosure

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature